

# Delia Goletti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1609954/publications.pdf>

Version: 2024-02-01

275  
papers

20,636  
citations

11651

70  
h-index

12597

132  
g-index

279  
all docs

279  
docs citations

279  
times ranked

28190  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	Towards tuberculosis elimination: an action framework for low-incidence countries. <i>European Respiratory Journal</i> , 2015, 45, 928-952.	6.7	608
3	Interferon- $\gamma$ release assays for the diagnosis of latent <i>Mycobacterium tuberculosis</i> infection: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2011, 37, 88-99.	6.7	490
4	LTBI: latent tuberculosis infection or lasting immune responses to <i>M. tuberculosis</i> ? A TBNET consensus statement. <i>European Respiratory Journal</i> , 2009, 33, 956-973.	6.7	487
5	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2010, 36, 1185-1206.	6.7	444
6	Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. <i>Journal of Infection</i> , 2020, 81, 318-356.	3.3	358
7	Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. <i>Nature Medicine</i> , 1999, 5, 643-650.	30.7	288
8	Effect of <i>Mycobacterium tuberculosis</i> on HIV replication. Role of immune activation. <i>Journal of Immunology</i> , 1996, 157, 1271-8.	0.8	280
9	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. <i>European Respiratory Journal</i> , 2020, 56, 2001398.	6.7	273
10	Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2014, 44, 23-63.	6.7	256
11	MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. <i>Journal of Clinical Investigation</i> , 2013, 123, 4836-4848.	8.2	245
12	ESX-1 dependent impairment of autophagic flux by <i>Mycobacterium tuberculosis</i> in human dendritic cells. <i>Autophagy</i> , 2012, 8, 1357-1370.	9.1	237
13	Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 11-34.	2.4	235
14	The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2012, 40, 990-1013.	6.7	211
15	Use of a T Cell $\gamma$ -Based Assay for Monitoring Efficacy of Antituberculosis Therapy. <i>Clinical Infectious Diseases</i> , 2004, 38, 754-756.	5.8	203
16	Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1168-1176.	5.6	196
17	Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. <i>Pulmonology</i> , 2020, 26, 233-240.	2.1	178
18	JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. <i>Science Advances</i> , 2021, 7, .	10.3	176

#	ARTICLE	IF	CITATIONS
19	<i>Mycobacterium tuberculosis</i> -specific CD8 <sup>+</sup> T cells are functionally and phenotypically different between latent infection and active disease. <i>European Journal of Immunology</i> , 2013, 43, 1568-1577.	2.9	172
20	Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. <i>Pulmonology</i> , 2021, 27, 151-165.	2.1	172
21	Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities. <i>Journal of Infectious Diseases</i> , 2020, 222, 1807-1815.	4.0	167
22	Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. <i>European Respiratory Journal</i> , 2016, 48, 1751-1763.	6.7	165
23	Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. <i>Journal of Infection</i> , 2020, 81, 647-679.	3.3	155
24	Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. <i>Autoimmunity Reviews</i> , 2015, 14, 503-509.	5.8	150
25	Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease. <i>Respirology</i> , 2018, 23, 455-466.	2.3	150
26	Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. <i>Blood</i> , 1999, 93, 4044-58.	1.4	149
27	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune) Tj ETQq1 1 0.784314 rgBT /Overlock 139 24. S10-S20.	6.0	139
28	Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful Treatment. <i>PLoS Pathogens</i> , 2016, 12, e1005687.	4.7	138
29	Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). <i>Vaccine</i> , 2001, 19, 2862-2877.	3.8	135
30	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2709-2712.	4.3	133
31	QuantIFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. <i>European Respiratory Journal</i> , 2009, 33, 586-593.	6.7	130
32	Tuberculosis Biomarkers: From Diagnosis to Protection. <i>Gastroenterology Insights</i> , 2016, 8, 6568.	1.2	129
33	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020, 92, S15-S25.	3.3	126
34	Bronchoalveolar Lavage Enzyme-linked Immunospot for a Rapid Diagnosis of Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 666-673.	5.6	125
35	Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. <i>Neurology</i> , 2022, 98, .	1.1	125
36	HIV replication in CD4 <sup>+</sup> T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous $\alpha$ -chemokines and the viral inductive effects of other endogenous cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 14076-14081.	7.1	119

#	ARTICLE	IF	CITATIONS
37	Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. <i>European Respiratory Journal</i> , 2010, 36, 135-142.	6.7	119
38	First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. <i>European Respiratory Journal</i> , 2016, 48, 1411-1419.	6.7	119
39	Region of Difference 1 Antigen-Specific CD4+Memory T Cells Correlate with a Favorable Outcome of Tuberculosis. <i>Journal of Infectious Diseases</i> , 2006, 194, 984-992.	4.0	113
40	A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with <i>M. tuberculosis</i> . <i>Tuberculosis</i> , 2011, 91, 260-267.	1.9	113
41	Lack of CD27 <sup>+</sup> CD45RA <sup>+</sup> CD45RO <sup>+</sup> T Cell Effectors in Immunocompromised Hosts and During Active Pulmonary Tuberculosis. <i>Journal of Immunology</i> , 2002, 168, 1484-1489.	0.8	104
42	A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. <i>Clinical Microbiology and Infection</i> , 2021, 27, 286.e7-286.e13.	6.0	104
43	Risk Assessment of Tuberculosis in Contacts by IFN- $\gamma$ Release Assays. A Tuberculosis Network European Trials Group Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1176-1184.	5.6	101
44	First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. <i>Journal of Infection</i> , 2016, 73, 588-597.	3.3	101
45	IFN- $\gamma$ /TNF- $\alpha$ specific-cells and effector memory phenotype associate with active tuberculosis. <i>Journal of Infection</i> , 2013, 66, 475-486.	3.3	100
46	Prevalence, Incidence and Correlates of HHV-8/KSHV Infection and Kaposi's Sarcoma in Renal and Liver Transplant Recipients. <i>Journal of Infection</i> , 2001, 43, 195-199.	3.3	97
47	Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. <i>Mediators of Inflammation</i> , 2017, 2017, 1-15.	3.0	93
48	On tuberculosis and COVID-19 co-infection. <i>European Respiratory Journal</i> , 2020, 56, 2002328.	6.7	93
49	Detection of interleukin-2 in addition to interferon- $\gamma$ discriminates active tuberculosis patients, latently infected individuals, and controls. <i>Clinical Microbiology and Infection</i> , 2010, 16, 1282-1284.	6.0	92
50	Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. <i>Journal of Infection</i> , 2014, 69, 533-545.	3.3	90
51	Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance. <i>Journal of rheumatology Supplement</i> , The, 2014, 91, 47-55.	2.2	89
52	Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis. <i>Tuberculosis</i> , 2017, 106, 38-43.	1.9	89
53	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	6.7	89
54	Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages. <i>PLoS ONE</i> , 2017, 12, e0171358.	2.5	88

#	ARTICLE	IF	CITATIONS
55	Accuracy of Immunodiagnostic Tests for Active Tuberculosis Using Single and Combined Results: A Multicenter TBNET-Study. <i>PLoS ONE</i> , 2008, 3, e3417.	2.5	88
56	First independent evaluation of QuantiFERON-TB Plus performance. <i>European Respiratory Journal</i> , 2016, 47, 1587-1590.	6.7	87
57	Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. <i>European Respiratory Journal</i> , 2021, 58, 2101786.	6.7	86
58	Selected RD1 Peptides for Active Tuberculosis Diagnosis: Comparison of a Gamma Interferon Whole-Blood Enzyme-Linked Immunosorbent Assay and an Enzyme-Linked Immunospot Assay. <i>Vaccine Journal</i> , 2005, 12, 1311-1316.	3.1	80
59	Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor- $\alpha$ (TNF- $\alpha$ ) Targeted Biologics and Recently Licensed TNF- $\alpha$ Inhibitors: Data from Clinical Trials and National Registries. <i>Journal of rheumatology Supplement, The</i> , 2014, 91, 56-64.	2.2	80
60	Performance of the Tuberculin Skin Test and Interferon- $\gamma$ Release Assays: An Update on the Accuracy, Cutoff Stratification, and New Potential Immune-based Approaches. <i>Journal of rheumatology Supplement, The</i> , 2014, 91, 24-31.	2.2	80
61	Cross-linking of CD30 induces HIV expression in chronically infected T cells. <i>Immunity</i> , 1995, 2, 587-596.	14.3	78
62	Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. <i>Clinical Microbiology and Infection</i> , 2006, 12, 544-550.	6.0	78
63	Characterization of regulatory T cells identified as CD4+CD25highCD39+ in patients with active tuberculosis. <i>Clinical and Experimental Immunology</i> , 2009, 156, 463-470.	2.6	78
64	Combined Use of Mycobacterium tuberculosis-specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis. <i>Clinical Infectious Diseases</i> , 2015, 60, 432-437.	5.8	75
65	Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices. <i>European Respiratory Journal</i> , 2016, 48, 808-817.	6.7	75
66	Cytometric detection of antigen-specific IFN- $\gamma$ /IL-2 secreting cells in the diagnosis of tuberculosis. <i>BMC Infectious Diseases</i> , 2009, 9, 99.	2.9	74
67	IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. <i>BMC Infectious Diseases</i> , 2011, 11, 135.	2.9	74
68	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. <i>Drugs</i> , 2020, 80, 1929-1946.	10.9	74
69	Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. <i>European Respiratory Journal</i> , 2010, 35, 619-626.	6.7	73
70	Can we predict tuberculosis cure? What tools are available?. <i>European Respiratory Journal</i> , 2018, 52, 1801089.	6.7	73
71	Is IP-10 an Accurate Marker for Detecting M. tuberculosis-Specific Response in HIV-Infected Persons?. <i>PLoS ONE</i> , 2010, 5, e12577.	2.5	73
72	Methylated HBHA Produced in M. smegmatis Discriminates between Active and Non-Active Tuberculosis Disease among RD1-Responders. <i>PLoS ONE</i> , 2011, 6, e18315.	2.5	72

#	ARTICLE	IF	CITATIONS
73	Immunosuppressive Therapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients. <i>Frontiers in Immunology</i> , 2021, 12, 740249.	4.8	70
74	Alpha Interferon Inhibits Human Herpesvirus 8 (HHV-8) Reactivation in Primary Effusion Lymphoma Cells and Reduces HHV-8 Load in Cultured Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , 1999, 73, 4029-4041.	3.4	70
75	miRNA Signatures in Sera of Patients with Active Pulmonary Tuberculosis. <i>PLoS ONE</i> , 2013, 8, e80149.	2.5	70
76	Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. <i>International Journal of Tuberculosis and Lung Disease</i> , 2008, 12, 146-51.	1.2	68
77	Granulocytic Myeloid Derived Suppressor Cells Expansion during Active Pulmonary Tuberculosis Is Associated with High Nitric Oxide Plasma Level. <i>PLoS ONE</i> , 2015, 10, e0123772.	2.5	67
78	IP-10 detection in urine is associated with lung diseases. <i>BMC Infectious Diseases</i> , 2010, 10, 333.	2.9	65
79	QuantIFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. <i>Journal of Infection</i> , 2019, 79, 444-453.	3.3	64
80	Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. <i>Apmis</i> , 2020, 128, 92-103.	2.0	64
81	Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. <i>International Journal of Infectious Diseases</i> , 2021, 113, S82-S87.	3.3	64
82	Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 183-192.	3.4	63
83	Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 35-54.	2.4	62
84	IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. <i>Journal of Infection</i> , 2012, 65, 49-59.	3.3	61
85	Janus-faced liposomes enhance antimicrobial innate immune response in <i>Mycobacterium tuberculosis</i> infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1360-8.	7.1	60
86	Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. <i>Antibiotics</i> , 2021, 10, 272.	3.7	60
87	The In Vitro Induction of Human Immunodeficiency Virus (HIV) Replication in Purified Protein Derivative-Positive HIV-Infected Persons by Recall Antigen Response to <i>Mycobacterium tuberculosis</i> Is the Result of a Balance of the Effects of Endogenous Interleukin-2 and Proinflammatory and Antiinflammatory Cytokines. <i>Journal of Infectious Diseases</i> , 1998, 177, 1332-1338.	4.0	59
88	Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. <i>Clinical and Experimental Immunology</i> , 2007, 150, 91-98.	2.6	59
89	The definition of tuberculosis infection based on the spectrum of tuberculosis disease. <i>Breathe</i> , 2021, 17, 210079.	1.3	59
90	IFN- $\gamma$ , but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. <i>Journal of Infection</i> , 2010, 61, 133-143.	3.3	57

#	ARTICLE	IF	CITATIONS
91	HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF- $\alpha$ ) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. <i>International Journal of Rheumatology</i> , 2014, 2014, 1-9.	1.6	57
92	Baricitinib Therapy in Covid-19 Pneumonia – An Unmet Need Fulfilled. <i>New England Journal of Medicine</i> , 2021, 384, 867-869.	27.0	56
93	Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to <i>Mycobacterium tuberculosis</i> : a pilot study. <i>Respiratory Research</i> , 2007, 8, 5.	3.6	54
94	Detection of Pulmonary tuberculosis: comparing MR imaging with HRCT. <i>BMC Infectious Diseases</i> , 2011, 11, 243.	2.9	54
95	Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis. <i>Journal of Infection</i> , 2015, 71, 526-533.	3.3	54
96	Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine. <i>Microorganisms</i> , 2021, 9, 1315.	3.6	54
97	The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1784-1789.	6.0	54
98	Higher Frequency of T-Cell Response to <i>M. tuberculosis</i> Latency Antigen Rv2628 at the Site of Active Tuberculosis Disease than in Peripheral Blood. <i>PLoS ONE</i> , 2011, 6, e27539.	2.5	54
99	Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 501-512.	4.4	53
100	New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. <i>BMC Infectious Diseases</i> , 2009, 9, 182.	2.9	51
101	The Spectrum of Tuberculosis Infection: New Perspectives in the Era of Biologics. <i>Journal of rheumatology Supplement</i> , The, 2014, 91, 11-16.	2.2	50
102	COVID-19 effects on tuberculosis care in Sierra Leone. <i>Pulmonology</i> , 2021, 27, 67-69.	2.1	50
103	Identification of Early Secretory Antigen Target-6 Epitopes for the Immunodiagnosis of Active Tuberculosis. <i>Molecular Medicine</i> , 2003, 9, 105-111.	4.4	49
104	Blood or Urine IP-10 Cannot Discriminate between Active Tuberculosis and Respiratory Diseases Different from Tuberculosis in Children. <i>BioMed Research International</i> , 2015, 2015, 1-11.	1.9	47
105	Acute Human Immunodeficiency Virus Replication Causes a Rapid and Persistent Impairment of CD4 <sup>+</sup> T Cells in Chronically Infected Patients Undergoing Structured Treatment Interruption. <i>Journal of Infectious Diseases</i> , 2002, 186, 847-850.	4.0	46
106	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 519-532.	3.4	45
107	Specific T Cells Restore the Autophagic Flux Inhibited by <i>Mycobacterium tuberculosis</i> in Human Primary Macrophages. <i>Journal of Infectious Diseases</i> , 2012, 205, 1425-1435.	4.0	44
108	Blood and urine inducible protein 10 as potential markers of disease activity. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1554-1561.	1.2	44



#	ARTICLE	IF	CITATIONS
109	In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. <i>Journal of Infection</i> , 2021, 82, 58-66.	3.3	44
110	Development of Potent Inhibitors of the <i>Mycobacterium tuberculosis</i> Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages. <i>ChemMedChem</i> , 2018, 13, 422-430.	3.2	43
111	Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis. <i>Frontiers in Immunology</i> , 2018, 9, 2427.	4.8	43
112	Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients. <i>International Journal of Infectious Diseases</i> , 2021, 106, 338-347.	3.3	43
113	Evaluation of IP-10 in QuantiFERON-Plus as biomarker for the diagnosis of latent tuberculosis infection. <i>Tuberculosis</i> , 2018, 111, 147-153.	1.9	42
114	The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. <i>International Journal of Infectious Diseases</i> , 2022, 124, S12-S19.	3.3	42
115	Inhibition of HIV-1 Replication in Monocyte-Derived Macrophages by <i>Mycobacterium tuberculosis</i> . <i>Journal of Infectious Diseases</i> , 2004, 189, 624-633.	4.0	39
116	Response to <i>M. tuberculosis</i> selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. <i>BMC Infectious Diseases</i> , 2008, 8, 11.	2.9	39
117	Differential Recognition of <i>Mycobacterium tuberculosis</i> Specific Epitopes as a Function of Tuberculosis Disease History. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 772-781.	5.6	39
118	Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. <i>Journal of Infection</i> , 2020, 80, 536-546.	3.3	38
119	Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. <i>International Journal of Infectious Diseases</i> , 2021, 107, 247-250.	3.3	38
120	Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	38
121	Accuracy of QuantiFERON-TB Gold Test for Tuberculosis Diagnosis in Children. <i>PLoS ONE</i> , 2015, 10, e0138952.	2.5	37
122	The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications. <i>International Journal of Infectious Diseases</i> , 2017, 56, 45-53.	3.3	37
123	Clinical isolates of the modern <i>Mycobacterium tuberculosis</i> lineage 4 evade host defense in human macrophages through eluding IL-1 $\beta$ -induced autophagy. <i>Cell Death and Disease</i> , 2018, 9, 624.	6.3	37
124	Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2022, 13, 846753.	4.8	37
125	False-negative interferon- $\gamma$ release assay results in active tuberculosis: a TBNET study. <i>European Respiratory Journal</i> , 2015, 45, 279-283.	6.7	36
126	Coordinated cellular and humoral immune responses after two-dose SARS-CoV2 mRNA vaccination in liver transplant recipients. <i>Liver International</i> , 2022, 42, 180-186.	3.9	36



#	ARTICLE	IF	CITATIONS
127	A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. <i>Tuberculosis</i> , 2015, 95, 713-721.	1.9	35
128	Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2019, 25, 169-177.	6.0	35
129	Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees. <i>European Respiratory Journal</i> , 2016, 47, 1345-1347.	6.7	34
130	Pulmonary cryptosporidiosis in an AIDS patient: successful treatment with paromomycin plus azithromycin. <i>International Journal of STD and AIDS</i> , 2005, 16, 515-517.	1.1	33
131	Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment. <i>Journal of Infection</i> , 2013, 66, 346-356.	3.3	33
132	Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions. <i>Frontiers in Immunology</i> , 2018, 9, 1456.	4.8	33
133	Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 415-425.	2.4	33
134	Inhibition of HECT E3 ligases as potential therapy for COVID-19. <i>Cell Death and Disease</i> , 2021, 12, 310.	6.3	33
135	IL-4 specific-response in whole blood associates with human Cystic Echinococcosis and cyst activity. <i>Journal of Infection</i> , 2015, 70, 299-306.	3.3	32
136	Association of baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered cohort study. <i>International Journal of Infectious Diseases</i> , 2020, 100, 199-206.	3.3	32
137	Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1701-1712.	9.1	32
138	Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection. <i>PLoS ONE</i> , 2017, 12, e0183846.	2.5	31
139	Managing latent tuberculosis infection and tuberculosis in children. <i>Pulmonology</i> , 2018, 24, 106-114.	2.1	31
140	Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine. <i>Scientific Reports</i> , 2022, 12, 6687.	3.3	31
141	Autophagy in Mycobacterium tuberculosis infection: A passepartout to flush the intruder out?. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 335-343.	7.2	30
142	Combined use of Quantiferon and HBHA-based IGRA supports tuberculosis diagnosis and therapy management in children. <i>Journal of Infection</i> , 2018, 77, 526-533.	3.3	30
143	Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. <i>European Respiratory Journal</i> , 2020, 55, 1901957.	6.7	30
144	Different Cytokine Production and Effector/Memory Dynamics of $\hat{I}\hat{\pm}\hat{I}^{2+}$ or $\hat{I}\hat{3}\hat{I}^{+}$ T-Cell Subsets in the Peripheral Blood of Patients with Active Pulmonary Tuberculosis. <i>International Journal of Immunopathology and Pharmacology</i> , 2003, 16, 247-252.	2.1	29

#	ARTICLE	IF	CITATIONS
145	Effect of cellular differentiation on cytokine-induced expression of human immunodeficiency virus in chronically infected promonocytic cells: dissociation of cellular differentiation and viral expression. <i>Journal of Virology</i> , 1995, 69, 2540-2546.	3.4	29
146	Clinical standards for the diagnosis, treatment and prevention of TB infection. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 190-205.	1.2	29
147	Use of Whole-Blood Samples in In-House Bulk and Single-Cell Antigen-Specific Gamma Interferon Assays for Surveillance of Mycobacterium tuberculosis Infections. <i>Vaccine Journal</i> , 2008, 15, 327-337.	3.1	27
148	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. <i>European Respiratory Journal</i> , 2018, 52, 1800946.	6.7	27
149	Polyfunctional Specific Response to Echinococcus Granulosus Associates to the Biological Activity of the Cysts. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004209.	3.0	27
150	Modulation of endogenous IL-1 beta and IL-1 receptor antagonist results in opposing effects on HIV expression in chronically infected monocytic cells. <i>Journal of Immunology</i> , 1996, 156, 3501-8.	0.8	27
151	High urine IP-10 levels associate with chronic HCV infection. <i>Journal of Infection</i> , 2014, 68, 591-600.	3.3	26
152	Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey. <i>Jornal Brasileiro De Pneumologia</i> , 2017, 43, 380-392.	0.7	26
153	Tools to implement the World Health Organization End TB Strategy: Addressing common challenges in high and low endemic countries. <i>International Journal of Infectious Diseases</i> , 2020, 92, S60-S68.	3.3	26
154	Analysis of Natural Killer (NK) Cell Subsets Defined by the Expression of Two Novel Surface Antigens (EB6 and GL183) in AIDS and AIDS-Related Conditions. <i>Clinical Immunology and Immunopathology</i> , 1994, 70, 198-205.	2.0	25
155	Impaired CD4 T-Cell Count Response to Combined Antiretroviral Therapy in Antiretroviral-Naive HIV-Infected Patients Presenting With Tuberculosis as AIDS-Defining Condition. <i>Clinical Infectious Diseases</i> , 2012, 54, 853-861.	5.8	25
156	Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis. <i>Frontiers in Immunology</i> , 2021, 12, 725447.	4.8	25
157	KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults. <i>Tuberculosis</i> , 2016, 97, 163-171.	1.9	24
158	Human CD4 T-Cells With a Naive Phenotype Produce Multiple Cytokines During Mycobacterium Tuberculosis Infection and Correlate With Active Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1119.	4.8	24
159	Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 861-872.	2.4	24
160	Lack of Response to HBHA in HIV-Infected Patients with Latent Tuberculosis Infection. <i>Scandinavian Journal of Immunology</i> , 2016, 84, 344-352.	2.7	23
161	Transglutaminase type 2 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection. <i>Journal of Internal Medicine</i> , 2018, 283, 303-313.	6.0	23
162	Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection. <i>Scientific Reports</i> , 2018, 8, 15626.	3.3	23

#	ARTICLE	IF	CITATIONS
163	Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e426-e438.	5.8	23
164	Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy. <i>PLoS ONE</i> , 2019, 14, e0212948.	2.5	22
165	TB and COVID-19 co-infection: rationale and aims of a global study. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 78-80.	1.2	22
166	Relevance of QuantiFERON-TB Gold Plus and Heparin-Binding Hemagglutinin Interferon- $\gamma$ Release Assays for Monitoring of Pulmonary Tuberculosis Clearance: A Multicentered Study. <i>Frontiers in Immunology</i> , 2020, 11, 616450.	4.8	22
167	Antibody Subclass and Glycosylation Shift Following Effective TB Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 679973.	4.8	22
168	Impact of antiretroviral and tuberculosis therapies on CD4 + and CD8 + HIV/M. tuberculosis-specific T-cell in co-infected subjects. <i>Immunology Letters</i> , 2018, 198, 33-43.	2.5	21
169	Impact of the global COVID-19 outbreak on the management of other communicable diseases. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 547-548.	1.2	21
170	Humoral and cellular responses to spike of $\gamma$ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases. <i>International Journal of Infectious Diseases</i> , 2022, 121, 24-30.	3.3	21
171	Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 55-61.	2.4	20
172	Multi-country evaluation of RISK6, a 6-gene blood transcriptomic signature, for tuberculosis diagnosis and treatment monitoring. <i>Scientific Reports</i> , 2021, 11, 13646.	3.3	20
173	Immune-Guided Therapy of COVID-19. <i>Cancer Immunology Research</i> , 2022, 10, 384-402.	3.4	20
174	Cystic Echinococcosis in a Single Tertiary Care Center in Rome, Italy. <i>BioMed Research International</i> , 2013, 2013, 1-9.	1.9	19
175	Use of several immunological markers to model the probability of active tuberculosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 169-171.	1.8	19
176	Preventing and controlling tuberculosis among refugees in Europe: more is needed. <i>European Respiratory Journal</i> , 2016, 48, 272-274.	6.7	19
177	Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients. <i>Molecular Immunology</i> , 2020, 120, 187-195.	2.2	19
178	Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection. <i>Journal of Translational Medicine</i> , 2021, 19, 272.	4.4	19
179	Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. <i>Molecular Medicine</i> , 2003, 9, 105-11.	4.4	19
180	Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 137.	3.9	18

#	ARTICLE	IF	CITATIONS
181	New synthetic lipid antigens for rapid serological diagnosis of tuberculosis. PLoS ONE, 2017, 12, e0181414.	2.5	18
182	Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy. Infection, 2021, 49, 1061-1064.	4.7	18
183	Multi-omics approach to COVID-19: a domain-based literature review. Journal of Translational Medicine, 2021, 19, 501.	4.4	18
184	Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis. Frontiers in Neurology, 2022, 13, .	2.4	18
185	Genetic Confirmation of Quinine-Resistant Plasmodium falciparum Malaria Followed by Postmalaria Neurological Syndrome in a Traveler from Mozambique. Journal of Clinical Microbiology, 2004, 42, 5424-5426.	3.9	17
186	Restarting Biologics and Management of Patients with Flares of Inflammatory Rheumatic Disorders or Psoriasis During Active Tuberculosis Treatment. Journal of rheumatology Supplement, The, 2014, 91, 78-82.	2.2	17
187	First description of agonist and antagonist IP-10 in urine of patients with active TB. International Journal of Infectious Diseases, 2019, 78, 15-21.	3.3	17
188	Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study. Journal of Clinical Medicine, 2021, 10, 2388.	2.4	17
189	Tuberculosis in Sheltered Homeless Population of Rome: An Integrated Model of Recruitment for Risk Management. Scientific World Journal, The, 2012, 2012, 1-7.	2.1	16
190	Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases. Journal of Infection, 2019, 79, 15-23.	3.3	16
191	Common and Rare Hematological Manifestations and Adverse Drug Events during Treatment of Active TB: A State of Art. Microorganisms, 2021, 9, 1477.	3.6	16
192	Tbnet â€” Collaborative research on tuberculosis in Europe. European Journal of Microbiology and Immunology, 2012, 2, 264-274.	2.8	15
193	A Toolbox for Tuberculosis (TB) Diagnosis: An Indian Multicentric Study (2006â€”2008). Evaluation of QuantiFERON-TB Gold in Tube for TB Diagnosis. PLoS ONE, 2013, 8, e73579.	2.5	15
194	Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review. Expert Opinion on Drug Safety, 2016, 15, 3-10.	2.4	15
195	Impact of Prior Influenza and Pneumococcal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination. Vaccines, 2021, 9, 615.	4.4	15
196	World TB Day 2022: Revamping and Reshaping Global TB Control Programs by Advancing Lessons learnt from the COVID-19 pandemic. International Journal of Infectious Diseases, 2022, 124, S1-S3.	3.3	15
197	The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy: a review from the ESCMYC study group. European Respiratory Review, 2022, 31, 210218.	7.1	15
198	Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal, 2022, 59, 2200388.	6.7	15

#	ARTICLE	IF	CITATIONS
199	HIV/HCV co-infection: putting the pieces of the puzzle together. <i>Cell Death and Differentiation</i> , 2003, 10, S25-S26.	11.2	14
200	The Mycobacterial HBHA Protein: A Promising Biomarker for Tuberculosis. <i>Current Medicinal Chemistry</i> , 2019, 26, 2051-2060.	2.4	14
201	IP-10 contributes to the inhibition of mycobacterial growth in an ex vivo whole blood assay. <i>International Journal of Medical Microbiology</i> , 2019, 309, 299-306.	3.6	14
202	Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis. <i>BMC Infectious Diseases</i> , 2019, 19, 882.	2.9	14
203	What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1453-1455.	6.0	14
204	Granzyme A as a potential biomarker of Mycobacterium tuberculosis infection and disease. <i>Immunology Letters</i> , 2015, 166, 87-91.	2.5	13
205	A Tâ€cell diagnostic test for cystic echinococcosis based on Antigen B peptides. <i>Parasite Immunology</i> , 2017, 39, e12499.	1.5	13
206	Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. <i>International Journal of Infectious Diseases</i> , 2020, 92, 62-68.	3.3	13
207	Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against Mycobacterium tuberculosis. <i>Frontiers in Immunology</i> , 2019, 10, 3042.	4.8	13
208	Transglutaminase 2 Regulates Innate Immunity by Modulating the STING/TBK1/IRF3 Axis. <i>Journal of Immunology</i> , 2021, 206, 2420-2429.	0.8	13
209	A Toolbox for Tuberculosis Diagnosis: An Indian Multicentric Study (2006-2008): Microbiological Results. <i>PLoS ONE</i> , 2012, 7, e43739.	2.5	12
210	A Toolbox for Tuberculosis (TB) Diagnosis: An Indian Multi-Centric Study (2006-2008); Evaluation of Serological Assays Based on PGL-Tb1 and ESAT-6/CFP10 Antigens for TB Diagnosis. <i>PLoS ONE</i> , 2014, 9, e96367.	2.5	12
211	Characterization of the CD4 and CD8 T-cell response in the QuantiFERON-TB Gold Plus kit. <i>International Journal of Mycobacteriology</i> , 2016, 5, S25-S26.	0.6	12
212	Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants. <i>Cell Death Discovery</i> , 2022, 8, .	4.7	12
213	The Chronically Infected Promonocytic Cell Line U1: A Model of HIV Expression Regulated by Cytokines. <i>ImmunoMethods</i> , 1993, 3, 50-55.	0.8	11
214	Diagnostic imaging of hepatic tuberculosis: case series. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 779-787.	1.2	11
215	PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease. <i>Frontiers in Immunology</i> , 2021, 12, 594376.	4.8	11
216	Impaired IFN-Î±-mediated signal in dendritic cells differentiates active from latent tuberculosis. <i>PLoS ONE</i> , 2018, 13, e0189477.	2.5	11

#	ARTICLE	IF	CITATIONS
217	Practices of therapeutic drug monitoring in tuberculosis: an international survey. <i>European Respiratory Journal</i> , 2022, 59, 2102787.	6.7	11
218	Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy. <i>Cells</i> , 2022, 11, 52.	4.1	11
219	INTERLEUKIN (IL)-4 INHIBITS PHORBOL-ESTER INDUCED HIV-1 EXPRESSION IN CHRONICALLY INFECTED U1 CELLS INDEPENDENTLY FROM THE AUTOCRINE EFFECT OF ENDOGENOUS TUMOUR NECROSIS FACTOR- $\alpha$ , IL-1 $\beta$ , 3.2 AND IL-1 RECEPTOR ANTAGONIST. <i>Cytokine</i> , 2002, 17, 28-35.		10
220	T Cell Responses to Commercial Mycobacterium tuberculosis--Specific Antigens in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2007, 45, 1652-1654.	5.8	10
221	Diagnostic Values of the QuantiFERON-TB Gold In-Tube Assay Carried out in China for Diagnosing Pulmonary Tuberculosis. <i>PLoS ONE</i> , 2015, 10, e0121021.	2.5	10
222	Preliminary data on precision of QuantiFERON-TB Plus performance. <i>European Respiratory Journal</i> , 2016, 48, 955-956.	6.7	10
223	The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 69-82.	2.4	10
224	Multicenter analysis of sputum microbiota in tuberculosis patients. <i>PLoS ONE</i> , 2020, 15, e0240250.	2.5	10
225	World Tuberculosis Day 2021 Theme "The Clock is Ticking" and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2021, 113, S1-S6.	3.3	10
226	Armed conflict and human displacement may lead to an increase in the burden of tuberculosis in Europe. <i>International Journal of Infectious Diseases</i> , 2022, 124, S104-S106.	3.3	10
227	Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20220087.	0.7	10
228	Global tuberculosis prevention: should we start from the beginning?. <i>European Respiratory Journal</i> , 2019, 54, 1901394.	6.7	9
229	Species specificity preliminary evaluation of an IL-6 based test for the differential diagnosis of human echinococcosis. <i>Parasite Immunology</i> , 2020, 42, e12695.	1.5	9
230	Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome. <i>International Journal of Infectious Diseases</i> , 2021, 103, 607-610.	3.3	9
231	In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses. <i>BioMed Research International</i> , 2021, 2021, 1-21.	1.9	9
232	Biologics and Tuberculosis Risk: The Rise and Fall of an Old Disease and Its New Resurgence. <i>Journal of rheumatology Supplement, The</i> , 2014, 91, 1-3.	2.2	8
233	Optimization of the autophagy measurement in a human cell line and primary cells by flow cytometry. <i>European Journal of Histochemistry</i> , 2019, 63, .	1.5	8
234	Making IGRA testing easier: First performance report of QIArearch QFT for tuberculosis infection diagnosis. <i>Pulmonology</i> , 2021, 28, 4-4.	2.1	8



#	ARTICLE	IF	CITATIONS
235	Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study. <i>Journal of Infection</i> , 2022, 84, 834-872.	3.3	8
236	Clearance of Human Herpesvirus 8 from Blood and Regression of Leukopenia Associated Aggressive Classic Kaposi's Sarcoma during Interferon- $\alpha$ Therapy: A Case Report. <i>Clinical Infectious Diseases</i> , 2001, 33, 1782-1785.	5.8	7
237	VIDAS <sup>®</sup> TB-IGRA reagents induce a CD4 <sup>+</sup> and CD8 <sup>+</sup> T-cell IFN- $\gamma$ response for both TB infection and active TB. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 65-68.	1.2	7
238	Screening for latent infection with <i>Mycobacterium tuberculosis</i> : a plea for targeted testing in low endemic regions. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 231-234.	3.1	6
239	Standard operating procedures for tuberculosis care. <i>European Respiratory Journal</i> , 2017, 49, 1700515.	6.7	6
240	Commemorating World TB Day 2020: "It's time to End the Global TB Epidemic." <i>International Journal of Infectious Diseases</i> , 2020, 92, S1-S4.	3.3	6
241	Accuracy of an experimental whole-blood test for detecting reactivation of echinococcal cysts. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009648.	3.0	6
242	<i>Mycobacterium tuberculosis</i> Immune Response in Patients With Immune-Mediated Inflammatory Disease. <i>Frontiers in Immunology</i> , 2021, 12, 716857.	4.8	6
243	Identification of Recent Tuberculosis Exposure Using QuantiFERON-TB Gold Plus, a Multicenter Study. <i>Microbiology Spectrum</i> , 2021, 9, e0097221.	3.0	6
244	Platelets accumulate in lung lesions of tuberculosis patients and inhibit T cell responses and <i>Mycobacterium tuberculosis</i> replication in macrophages. <i>European Journal of Immunology</i> , 2022, 52, 784-799.	2.9	6
245	Should Individuals Who Are Tuberculin Skin Test Negative and Positive to RD1 <sup>+</sup> IFN- $\gamma$ Assay Receive Preventive Therapy?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 198a-199.	5.6	5
246	Immune Status and Serial Quantiferon-TB Gold In-Tube Screening for Latent <i>Mycobacterium tuberculosis</i> Infection Among HIV-Infected Persons in a Country With a Low Tuberculosis Incidence. <i>Journal of Infectious Diseases</i> , 2015, 211, 1852-1853.	4.0	5
247	Antitubercular and anti-inflammatory properties screening of natural products from <i>Plectranthus</i> species. <i>Future Medicinal Chemistry</i> , 2018, 10, 1677-1691.	2.3	5
248	Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries?. <i>Frontiers in Public Health</i> , 2020, 8, 443.	2.7	5
249	In-Depth Immunophenotyping With Mass Cytometry During TB Treatment Reveals New T-Cell Subsets Associated With Culture Conversion. <i>Frontiers in Immunology</i> , 2022, 13, 853572.	4.8	5
250	The Loss of CMV-Specific CD27 <sup>+</sup> T-Cell Effectors in a Patient with Recurrences of CMV Retinitis Is Independent of HIV-1 Viremia. <i>Infection</i> , 2002, 30, 323-325.	4.7	4
251	Do human $\gamma\delta$ T cells respond to <i>M tuberculosis</i> protein antigens?. <i>Blood</i> , 2008, 112, 4776-4777.	1.4	4
252	Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 2097-2111.	2.0	4



#	ARTICLE	IF	CITATIONS
253	Do IFN- $\gamma$ -release assays predict the risk of TB? New evidence from a study on patients with silicosis. Expert Review of Anti-Infective Therapy, 2010, 8, 1105-1108.	4.4	3
254	Long-lasting tuberculous pleurisy. European Respiratory Journal, 2017, 49, 1700356.	6.7	3
255	Putting in Harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for Multidrug-Resistant Tuberculosis. , 2019, , .		3
256	Assay design for unambiguous identification and quantification of circulating pathogen-derived peptide biomarkers. Theranostics, 2022, 12, 2948-2962.	10.0	3
257	Increased Association of Pulmonary Thromboembolism and Tuberculosis during COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. Antibiotics, 2022, 11, 398.	3.7	3
258	Country-specific approaches to latent tuberculosis screening targeting migrants in EU/EEA* countries: A survey of national experts, September 2019 to February 2020. Eurosurveillance, 2022, 27, .	7.0	3
259	Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements. Expert Opinion on Drug Safety, 2022, 21, 613-623.	2.4	3
260	A Two-Step Approach for Screening Contacts of Active Tuberculosis. Infection, 2007, 35, 122-123.	4.7	2
261	Quantitative Pulmonary T-Cell Responses for the Diagnosis of Active Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 289-290.	5.6	2
262	Interferon- $\gamma$ release assays for the diagnosis of latent Mycobacterium tuberculosis infection. European Respiratory Journal, 2011, 38, 1238-1239.	6.7	2
263	Discordance between the QuantiFERON-TB Gold In-Tube and Tuberculin Skin Test: need for a further step?. European Respiratory Journal, 2015, 46, 1506-1509.	6.7	2
264	Editorial: Tuberculosis and Non-tuberculous Mycobacteria Infections: Control, Diagnosis and Treatment. Frontiers in Public Health, 2021, 9, 666187.	2.7	2
265	Bronchoalveolar lavage immunodiagnosis for tuberculosis suspects in Europe and Africa. Thorax, 2010, 65, 842-842.	5.6	1
266	Pathogenesis and Immunology of Tuberculosis. , 2021, , 19-27.		1
267	Omics and single molecule detection: the future of TB diagnostics. , 2012, , 144-153.		1
268	Diagnosis and treatment of latent tuberculosis infection. , 0, , 381-398.		1
269	Utilizzo di nuovi test immunologici nella diagnostica dell'infestazione da M. tuberculosis. Microbiologia Medica, 2006, 21, .	0.1	0
270	Update on clinical research of tuberculosis: a report from the European Respiratory Society. Expert Review of Respiratory Medicine, 2008, 2, 707-711.	2.5	0

#	ARTICLE	IF	CITATIONS
271	TB elimination: a dream or a reality? Key lessons from the ERS external course in Dubrovnik, Croatia. <i>Breathe</i> , 2013, 9, 458-461.	1.3	0
272	The best of respiratory infections from the 2015 European Respiratory Society International Congress. <i>ERJ Open Research</i> , 2016, 2, 00049-2016.	2.6	0
273	Severe chest allodynia as an unusual first presentation of hydatid disease: a case report. <i>BMC Infectious Diseases</i> , 2019, 19, 37.	2.9	0
274	Commemorating World Tuberculosis Day 2022: recent <i>ERJ</i> articles of critical relevance to ending TB and saving lives. <i>European Respiratory Journal</i> , 2022, 59, 2200149.	6.7	0
275	Biological Therapies and Tuberculosis Infection in Dermatology. , 0, , 1-5.		0